Overview

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, multicenter, open-label, dose-escalation study of DSTP3086S administered as a single agent by intravenous (IV) infusion to patients with metastatic Castration-Resistant Prostate Cancer (CRPC).
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.